“For prescription opioid dependence, buprenorphine detoxification is less effective than ongoing maintenance treatment, and increases the risk of overdose and other adverse events,” said Fiellin. “We ...
As a father, my heart belongs to my children. As the owner of an addiction treatment center, my thoughts are with my clients and how to help them return to their families. I recognize in these two ...
As a father, my heart belongs to my children. As the owner of an addiction treatment center, my thoughts are with my clients and how to help them return to their families. I recognize in these two ...
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet ...
Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence and should be used as part of a comprehensive treatment plan, which ...
In 2012, nearly 5 million people older than 12 years were reported to be nonmedical users of pain medications in the United States. [1] Effective and predictable long-term treatment for opioid use ...
For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School of Medicine ...
Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) for induction of buprenorphine maintenance ...
For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study. For treating patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback